1. Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment
    Jesus J. Benito-Lopez et al, 2023, Frontiers in Oncology CrossRef
  2. Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy
    Ran Gao et al, 2022, Frontiers in Immunology CrossRef
  3. Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects
    Xuefeng Wang et al, 2024, Frontiers in Immunology CrossRef
  4. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
    Jinming Liu et al, 2024, Frontiers in Immunology CrossRef
  5. Trial watch: IDO inhibitors in cancer therapy
    Julie Le Naour et al, 2020, OncoImmunology CrossRef
  6. Research Progress on the Relationship between Tumor Radiotherapy and TIM-3
    晨晨 矫, 2022, Advances in Clinical Medicine CrossRef
  7. Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
    Linfang Wu et al, 2022, Frontiers in Immunology CrossRef
  8. Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
    Rongjie Zhang et al, 2022, Frontiers in Pharmacology CrossRef
  9. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
    Yun Hua Lee et al, 2020, Frontiers in Immunology CrossRef
  10. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome
    R. Zou et al, 2021, Clinical and Translational Oncology CrossRef
  11. IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
    Linfang Wu et al, 2023, Journal of Oncology CrossRef
  12. Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy
    Roberta Liberato Pagni et al, 2022, Frontiers in Immunology CrossRef
  13. Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder
    Donghyun Kim et al, 2020, Journal of Clinical Medicine CrossRef
  14. Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer
    Enrica Marmonti et al, 2022, Cells CrossRef